A PHASE 1B, OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION STUDY OF THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF CERGUTUZUMAB AMUNALEUKIN, AN IMMUNOCYTOKINE, WHICH CONSISTS OF A VARIANT OF INTERLEUKIN-2 (IL-2v) TARGETING CARCINOEMBRYONIC ANTIGEN

Protocol: 
AAAR5186
Phase: 
I

A PHASE 1B, OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION STUDY OF THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF CERGUTUZUMAB AMUNALEUKIN, AN IMMUNOCYTOKINE, WHICH CONSISTS OF A VARIANT OF INTERLEUKIN-2 (IL-2v) TARGETING CARCINOEMBRYONIC ANTIGEN

Are you Eligible? (Inclusion Criteria)

You must:
1. Be ≥ 18 years of age
2. Have confirmed locally advanced and/ or metastatic solid tumor
3. Have radiologically measurable and clinically evaluable disease
4. Have a life expectancy of ≥ 12 weeks

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States